Evaluation of Atacand® (Candesartan) in Daily Medical Practice
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00837720
- Lead Sponsor
- AstraZeneca
- Brief Summary
This open label, non-interventional study is to show the efficacy of antihypertensive treatment with Atacand in hypertensive patients. Efficacy is to be evaluated based on the difference in systolic and diastolic blood pressure at baseline and at both follow-up visits.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 750
Inclusion Criteria
- a patient with arterial hypertension who has been prescribed Atacand according to physician's judgement, irrespective of the inclusion in the study
Exclusion Criteria
- hypersensitivity to candesartan or any other ingredient of Atacand
- liver function impairment and/or cholestasis
- severe renal insufficiency
- woman of child-bearing potential and not using appropriate contraceptive measures, pregnancy or lactation
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Systolic and diastolic blood pressure reduction 12 weeks
- Secondary Outcome Measures
Name Time Method Incidence and reasons of treatment discontinuation 12 weeks Patient treatment satisfaction (using 5-point answering scale) as the measure of the patient's overall tolerance 12 weeks Physician overall evaluation of the therapy (using 5-point answering scale) 12 weeks